Viyash Scientific Ltd

Sequent Scientific Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in technical indicators and robust quarterly financial results. The upgrade, effective from 19 Jan 2026, is underpinned by a combination of enhanced technical trends, strong profit growth, rising promoter confidence, and a valuation that, while expensive, is supported by recent performance metrics.

Sequent Scientific Ltd has seen its investment rating downgraded from Hold to Sell as of 13 January 2026, reflecting a complex interplay of deteriorating technical indicators, challenging long-term fundamentals, and valuation concerns despite recent positive quarterly results and rising promoter confidence.

Sequent Scientific Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from a mildly bullish trend to a sideways movement. Despite a recent downgrade in its Mojo Grade to Sell, the stock’s mixed technical signals across weekly and monthly charts suggest a complex outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

Sequent Scientific Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Sequent Scientific Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 02 Sep 2025. While this rating change occurred in early September, the analysis and financial metrics discussed here reflect the company’s current position as of 30 December 2025, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Sequent Scientific, a key player in the Pharmaceuticals & Biotechnology sector, is exhibiting a nuanced shift in its technical momentum as recent evaluation adjustments reflect a transition from a bullish to a mildly bullish trend. This development comes amid a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively paint a multifaceted picture of the stock’s near-term trajectory.

Sequent Scientific, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical parameters, reflecting evolving price momentum and mixed signals from key indicators such as MACD, RSI, and moving averages. The stock’s recent price movements and technical trends offer a nuanced picture for investors analysing its near-term trajectory.

Sequent Scien., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a period marked by contrasting performance indicators across quality, valuation, financial trends, and technical parameters.

Sequent Scientific, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Recent evaluation adjustments highlight a transition from a strongly bullish stance to a more tempered mildly bullish outlook, underscoring the importance of closely monitoring technical indicators such as MACD, RSI, moving averages, and other momentum oscillators.

Sequent Scien., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a revision in its market evaluation. This shift reflects a nuanced view of the company’s financial and technical parameters, highlighting both promising trends and ongoing challenges within its operational and valuation metrics.

Sequent Scientific experienced notable intraday weakness on 24 Nov 2025, touching a low of Rs 221.1 as the stock faced significant price pressure. The decline occurred amid broader market volatility, with the Sensex reversing sharply after a positive start to the day.

Sequent Scientific experienced a notable intraday decline on 20 Nov 2025, touching a low of Rs 234, reflecting a price pressure of 7.12% during the trading session. This movement contrasts with the broader market trend, where the Sensex recorded gains and reached a new 52-week high.

Sequent Scientific, a key player in the Pharmaceuticals & Biotechnology sector, reached a new 52-week high of Rs.260.3 today, marking a significant milestone in its stock performance. This peak reflects the stock’s sustained momentum over the past year amid a broader market environment showing cautious optimism.

Sequent Scientific recorded a robust intraday performance today, surging to a new 52-week high of Rs.249.15, marking a 7.69% rise during the trading session. This notable uptick outpaced the Pharmaceuticals & Biotechnology sector and the broader market, reflecting significant trading momentum.

Sequent Scientific, a key player in the Pharmaceuticals & Biotechnology sector, reached a new 52-week high of Rs.249.15 today, underscoring a notable phase of momentum in its stock performance. This milestone reflects the stock’s sustained upward trajectory amid a mixed market environment.

Sequent Scientific Ltd., a leading integrated animal health pharmaceutical company, reported consolidated net profit of ₹14.74 crores for Q2 FY26, marking an extraordinary 464.75% year-on-year surge from ₹2.61 crores in Q2 FY25. The stock, trading at ₹231.35 with a market capitalisation of ₹5,751 crores, has rallied 31.90% over the past three months, significantly outperforming the broader market. However, the impressive profit growth comes against a backdrop of stretched valuations and historical profitability challenges that warrant careful examination.